Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients

Ann Oncol. 2016 Sep;27(9):1810. doi: 10.1093/annonc/mdw208. Epub 2016 May 13.

Authors

C Cremolini¹, R Moretto¹, G Masi¹, A Falcone²

Affiliations

¹ Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy.
² Department of Oncology, Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa Department of Medical Oncology, University of Pisa, Pisa, Italy alfredo.falcone@med.unipi.it.

PMID: 27177861
DOI: 10.1093/annonc/mdw208

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Capecitabine*
Colorectal Neoplasms
Deoxycytidine / analogs & derivatives
Fluorouracil* / analogs & derivatives
Humans
Leucovorin
Organoplatinum Compounds
Oxaloacetates

Substances

Organoplatinum Compounds
Oxaloacetates
Deoxycytidine
Capecitabine
Leucovorin
Fluorouracil

Supplementary concepts

XELOX